Articles By Jack Cush, MD
Gastrointestinal Perforation Risk increased for Tofacitinib and Tocilizumab
Gastrointestinal perforations (GIP) are not historically believed to be a common or uncommon complication. Hence, when this was noted in the tocilizumab (TCZ) and tofacitinib (TOFA) developmental trials, it was a curious if not perplexing finding.
Read Article
Patients Undertreated and Uninformed on Pain Meds and NSAIDs
Pain management in the U.S. is at a vexing crossroad. The news tells us that narcotics are increasingly being restricted for their dangerous side effects and inappropriate use.
Read Article
Arhalofenate, URAT-1 Inhibitor, Being Developed for Gout
Good news for gout patients includes the recent approval of Zurampic (lesinurad), a URAT-1 inhibitor, and that effective urate-lowering therapy has significant long-term cardiovascular benefits.
Read Article
RheumNow Week in Review – 27 May 2016
Dr. Cush reviews highlights from this week on RheumNow.com.
Read Article
Mosquito Arthritis
In the last two years there have been increasing reports of mosquito-borne infectious arthritides. Dengue fever was best known until the introduction of viral infections due to chikungunya and Zika.
Read Article
IL-23 Inhibitor Effective in Crohn's Disease
Selective IL-23 inhibition has been touted to be the next great advance in the treatment of inflammatory bowel and psoriatic disease.
Read Article
Listen to the Patient…She’s Telling You the Diagnosis
I had a 20-minute visit scheduled with Mrs. Goldstein yesterday. She is a thin, foreign-born, older woman with rheumatoid arthritis, recently complicated by lymphoma. As I sat, I asked “where is your husband this morning”, as he usually attends her medical visits. I had already turned to the computer and started to bring up her file, meds, etc. There was a long pause before she finally answered.
Read Article
Opioid Prescriptions in Decline
In an era of increasing fears over narcotic abuse and narcotic-related deaths, the number of opioid prescriptions in the United States is finally falling, the according to the NY Times.
Read Article
TB Management Questions
The following is a compilation of several frequently asked questions regarding tuberculosis (TB) testing or treatment in patients on a TNF inhibitor (TNFi) or other biologic agents.
Read Article
ORBIT Study Shows Rituximab and TNF inhibitor Equivalence
The initial choice of biologic is crucial to long-term success. Yet there are few studies evaluating head-to-head differences in some of our most popular therapies.
Read Article
